Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.41 |
| ▸ | CDC42BPB | Q9Y5S2 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 8/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.39 |
| ▸ | PIK3C3 | Q8NEB9 | 5/20 | 0.38 |
| ▸ | ATR | Q13535 | 1/20 | 0.38 |
| ▸ | PRKDC | P78527 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23604060 | 0.78 | CHRNB4 (0.33) | — | |
| SCHEMBL3013753 | 0.69 | ROCK2 (0.47) | GBA1ROCK2ROCK1CDC42BPBATM | |
| SCHEMBL2603288 | 0.69 | SLC18A2 (0.49) | — | |
| SCHEMBL30801843 | 0.68 | SLC6A2 (0.37) | GBA1ROCK2ROCK1CDC42BPBATM | |
| SCHEMBL30801867 | 0.68 | SLC6A2 (0.37) | GBA1ROCK2ROCK1CDC42BPBATM | |
| SCHEMBL15999327 | 0.68 | ALDH1A1 (0.35) | PRKDC | |
| SCHEMBL23574056 | 0.67 | USP30 (0.38) | GBA1ROCK2ROCK1CDC42BPBATM | |
| SCHEMBL4331452 | 0.66 | SLC18A2 (0.46) | — | |
| SCHEMBL20419217 | 0.66 | SLC18A2 (0.46) | — | |
| SCHEMBL2606119 | 0.66 | ADRA2A (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198263-A1 | FUSED BICYCLIC COMPOUNDS USEFUL AS UBIQUITIN-SPECIFIC PEPTIDASE 30 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198263-A1 | FUSED BICYCLIC COMPOUNDS USEFUL AS UBIQUITIN-SPECIFIC PEPTIDASE 30 INHIBITORS | USP30, UCHL1, ADRM1 | GBA1 858/4885ROCK2 4284/4885ROCK1 4146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.